Marinus Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Marinus Pharmaceuticals CEO'su Scott Braunstein, Aug2019 tarihinde atandı, in görev süresi 5.25 yıldır. in toplam yıllık tazminatı $ 3.21M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.2% maaş ve 79.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.22% ine doğrudan sahiptir ve bu hisseler $ 36.63K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4 yıl ve 4.6 yıldır.
Anahtar bilgiler
Scott Braunstein
İcra Kurulu Başkanı
US$3.2m
Toplam tazminat
| CEO maaş yüzdesi | 20.2% |
| CEO görev süresi | 5.3yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 4yrs |
| Yönetim Kurulu ortalama görev süresi | 4.6yrs |
Son yönetim güncellemeleri
Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$149m |
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$3m | US$650k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$3m | US$591k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$4m | US$574k | -US$99m |
| Sep 30 2021 | n/a | n/a | -US$88m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$4m | US$556k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$74m |
| Jun 30 2020 | n/a | n/a | -US$72m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$2m | US$305k | -US$54m |
| Sep 30 2019 | n/a | n/a | -US$49m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$210k | n/a | -US$37m |
Tazminat ve Piyasa: Scott 'nin toplam tazminatı ($USD 3.21M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 651.15K ).
Tazminat ve Kazançlar: Scott şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Scott Braunstein (61 yo)
5.3yrs
Görev süresi
US$3,214,100
Tazminat
Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Chairman | 5.3yrs | US$3.21m | 0.22% $ 36.6k | |
| COO, CFO & Treasurer | 3.6yrs | US$1.44m | 0.031% $ 5.3k | |
| Chief Medical Officer | 5.1yrs | US$1.37m | 0.031% $ 5.3k | |
| Chief Scientific Officer | no data | Veri yok | Veri yok | |
| Senior VP of Investor Relations | 1.4yrs | Veri yok | Veri yok | |
| Senior VP | 4.4yrs | Veri yok | 0.022% $ 3.7k | |
| Director of Corporate Communications & Investor Relations | 1.4yrs | Veri yok | Veri yok | |
| Chief Regulatory & Quality Assurance Officer | no data | Veri yok | Veri yok | |
| Chief Commercial Officer | 4yrs | Veri yok | 0.034% $ 5.8k | |
| Chief Chemistry | no data | Veri yok | Veri yok |
4.0yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim: MRNS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Chairman | 6.2yrs | US$3.21m | 0.22% $ 36.6k | |
| Lead Independent Director | 15.9yrs | US$202.52k | 0.025% $ 4.3k | |
| Independent Director | 4.9yrs | US$162.52k | 0.010% $ 1.7k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 8.2yrs | US$160.02k | 0.011% $ 1.9k | |
| Independent Director | 3.7yrs | US$154.74k | 0.012% $ 2.0k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.3yrs | US$157.52k | 0.0096% $ 1.6k | |
| Independent Director | 1.8yrs | US$249.21k | Veri yok | |
| Independent Director | 1.6yrs | US$304.81k | 0.0044% $ 738.5 | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
4.6yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: MRNS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).